Investor Announcements - 2016

Pages:

TR-1 notification of major interest in shares

21^st Mar 2016

Second Price Monitoring Extension

17^th Mar 2016

Notice of Results

17^th Mar 2016

EKF Diagnostics Holdings plc announces Notice of Results.

Trading update

3^rd Feb 2016

EKF Diagnostics Holdings plc announces a trading update for the year ended 31 December 2015.

TR-1 notification of major interest in shares

20^th Jan 2016

TR-1 notification of major interest in shares

18^th Jan 2016

TR-1 notification of major interest in shares

15^th Jan 2016

Pages:

Archive

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

New study identifies bugs that help runners

A recent article in Nature Medicine by Scheiman et al has identified a strain of gut microbes present in marathon runners that improves run times. The scientists at Harvard and the Joslin Institute took poop samples from 15 runners at the 2015 Boston marathon.

EKF at AACC - Anaheim, California 2019

Connect with global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory medicine.

EKF DiaSpect Tm hemoglobin analyzer supports anemia study in resource limited West Africa

Battery powered point-of-care analyzer demonstrated as ideal for operation in extreme temperatures and remote areas.

EKF at MEDLAB - Singapore 2019

EKF signs DiaSpect Tm U.S. distribution agreement with McKesson to launch McKesson Consult® Hb analyzer

FDA cleared POC hemoglobin analyzer to be sold across the USA by the market’s leading and most established healthcare distributor